The Locus of Fat Over-Accumulation as Predictor of Cardiometabolic Risks among Non Obese Normotensive Adults
Journal of Advances in Medicine and Medical Research,
Studies on Metabolic Syndrome (MS) have recently been narrowed down to fat over-accumulation but there is no consistency in the obesity requirements for any of the health risk scores and definitions, thus, the utility of anthropometric measures in cardiometabolic risks prediction among non-obese requires additional research. This cross sectional study assessed the relationships and predictabilities of visceral adiposity index (VAI) and Lipid accumulation product (LAP) for cardiometabolic risks among 174 non obese adults (91 males and 83 females) 35 - 70 years of age that was randomly selected for this study after their consent. Anthropometric evaluation included weight, height, hip and waist circumferences. BMI, Waist-height ratio and waist-hip ratio were calculated. Serum Triglyceride and High Density Lipoprotein measured in a 12 hour fasting condition (mmol/L) using standard laboratory techniques were recorded. The VAI and LAP scores were calculated using the gender-specific equations. Systolic blood pressure and Diastolic blood pressure were measured and MABP was calculated as: DBP + 1/3 Pulse Pressure (mm/Hg). The results showed significant correlations among LAP, VAI, WHTR, WHPR and BMI (p≤0.01). Multivariate correlations and regression analysis of measures of adiposity and MS features also showed that LAP had a greater impact on features of MS and superior to other adiposity measures in male and female (R2: 0.956; p≤0.01). In conclusion, this study shows that LAP is superior in predicting risks of lipid and visceral adipose over-accumulations than other measures of adiposity among non-obese adults. The use of LAP as an assessment tool for Risks of fat over-accumulations and its intervention among non-obese adults was suggested.
- Lipid adiposity product
- visceral adiposity index
- metabolic syndrome
- non-obese adults.
How to Cite
Tsai C. Metabolic syndrome in non-obese Taiwanese: New definition of metabolically obese, normal-weight individual. Chinese Medical Journal. 2009;122:2534-2539.
Tanko LB, Bagger YZ, Alexandersen P, Christiansen C, Larsen PJ. Peripheral adiposity and cardiovascular risk (letter). Circulation. 2003;108:e164.
Palaniappan L, Leon A, Simons MD, Simons J, Friedlander Y, John M. Comparison of usefulness of systolic, diastolic, and mean blood pressure and pulse pressure as predictors of cardiovascular death in patients ≥60 years of age (The Dubbo Study) American Journal of Cardiology. 2002;90(12):1398–1401.
Zhang C, Rexrode KM, Van Dam RM, Li TY, Hu FB. Abdominal obesity and the risk of all-cause, cardiovascular and cancer mortality: Sixteen years of follow-up in US women. Circulation. 2008;117(13);1658-1667
Ravikeerthy M, Nataraj T. A comparative study of cardiovascular parameters in obese and non-obese individuals. International Journal of Scientific and Research Publications. 2015;5(5),1:2250-3153.
Pascot A, Lemieux S, Lemieux I, Prud’homme D, Tremblay A, Bouchard C, Nadeau A, Couillard C, Tchernof A, Bergeron J, Despre´s JP. Age-related increase in visceral adipose tissue and body fat and the metabolic risk profile of premenopausal women. Diabetes Care. 1999;22:1471–1478.
DeNino WF, Tchernof A, Dionne IJ, Toth MJ, Ades PA, Sites CK, Poehlman ET. Contribution of abdominal adiposity to age-related differences in insulin sensitivity and plasma lipids in healthy nonobese women. Diabetes Care. 2001;24:925–932.
Amato MC, Giordano C, Massimo G, Angela C, Salvatore V, Massimo M, Aldo G. Visceral adiposity index a reliable indicator of visceral fat function associated with cardiometabolic. Risk Diabetes Care. 2010; 33:920–922.
Kahn HS. The lipid accumulation product performs better than the body mass index for recognizing cardiovascular risk: A population-based comparison. BMC Cardiovasc Disord. 2005;5:26.
Roriz AK, Passos LC De, Oliveira CC Evaluation of the accuracy of anthropometric clinical indicators of visceral fat in adults and elderly. PLoS One. 2014;9:10.
Ru,i L, Qi, L, Min C, Zegang Y, Lin L, Tingting Z, Yingchao H, Peng X. Visceral adiposity index, lipid accumulation product and intracranial atherosclerotic stenosis in middle-aged and elderly Chinese. The Nature.Com/Scientific Reports. 2016;7: 7951
Garcés MJ, Hernándezb J , Gloria Q, Miguel K, Mayra B, Arturo H, Juan C, Rosa Q, Armando E, Nayely G. Novel gender-specific visceral adiposity index for Mexican pediatric population. Revista Medica Del Hospital General de México. 2014;77(4):153-159.
Amato MC, Giuseppe P, Vittoria T, Gabriella M, Salvatore M, Carla G. Visceral adiposity index (VAI) is predictive of an altered adipokine profile in patients with type 2 diabetes. PLoS ONE. 2014;9(3).
Dung W, Cheung WW, Mak RH. Impact of obesity on kidney function and blood pressure in children. World Journal of Nephrology. 2017;4(2):223-229.
Mohammadreza B, Farzad H, Davoud K, Fereidoun AF. Prognostic significance of the complex “Visceral Adiposity Index” vs. simple anthropometric measures: Tehran lipid and glucose study. Cardiovasc Diabetol. 2012;11:20.
Wakabayashi I, Daimon TA. Strong association between lipid accumulation product and diabetes mellitus in Japanese women and men. Journal of Atherosclerosis and Thrombosis. 2014;21: 282–288.
Xia C et al. Lipid accumulation product is a powerful index for recognizing insulin resistance in non-diabetic individuals. Eur J Clin Nutr. 2012;66:1035–1038.
Guimarães MM, Dirceu BG, Allyson NM, Nathalia SG, Cláudia MF, Bruna G, Lucas M. Lipid accumulation product index in HIV-infected patients: A marker of cardiovascular risk braz j infect dis. 2018; 2(3):171–176.
Wakabayashi I. Associations of blood lipid-related indices with blood pressure and pulse pressure in middle-aged men. Metab Syndr Relat Disord. 2015;13:22–28.
Joachimescu AG, Brennan DM, Hoar BM, Hoogwerf BJ. The lipid accumulation product and all-cause mortality in patients at high cardiovascular risk: A PreCIS database study. Obesity (Silver Spring, Md). 2010;18:1836–1844.
Ding Y, Dongfeng G, Yanxuan Z, Wenjie H, Hengliang L, Qingshan Q. Significantly increased Visceral Adiposity Index in prehypertension. PLoS ONE. 2015;10(4).
Du T, Sun X, Huo R, Yu X. Visceral adiposity index, hypertriglyceridemic waist and risk of diabetes: The china health and nutrition survey. Int J Obes (Lond). 2009; 38:840–847.
Oh JY, Sung YA, Lee HJ. The visceral adiposity index as a predictor of insulin resistance in young women with polycystic ovary syndrome. Obesity. 2013;21:1690–1694.
Rui L, Qi L, Min C, Zegang Y, Lin L, Tingting Z, Yingchao H, Peng X. Visceral adiposity index, lipid accumulation product and intracranial atherosclerotic stenosis in middle-aged and elderly Chinese The Nature.Com/Scientific Reports. 2016;7: 7951.
Zhang X, Shu XO, Gao YT, Yang G, Matthews CE, Li Q, Li H, Jin F, Zheng W. Visceral adiposity and risk of coronary heart disease in relatively lean Chinese adults. Int J Cardiol. 2013;168:2141–2145.
Nazare JA, et al. Ethnic influences on the relations between abdominal subcutaneous and visceral adiposity, liver fat, and cardiometabolic risk profile: The international study of prediction of intra-abdominal adiposity and its relationship with cardiometabolic risk/intra-abdominal adiposity. Am J Clin Nutr. 2012;96:714–726.
Sharaye KO, Olorunshola KV, Ayo JO, Dikki, C. Correlation of obesity indicies and blood pressure among non-obese adults in Zaria, Northern Nigeria. Journal of Public Health and Epidemiology. 2014;6(1):8-13.
Mark W. Epidemiology: Study Design and Data Analysis. Chapman and Hall/CRC. 1999;202-203. ISBN 1-58488-009-0.
International Diabetic Federation (IDF). The IDF consensus worldwide definition of Metabolic Syndrome. IDF Communications, Avenue Emile De Mot 19, B-1000 Brussels, Belgium; 2005.
Taverna MJ, Martı´nez-Larrad MT, Gustavo F, Manuel S. Lipid accumulation product: a powerful marker of metabolic syndrome in healthy population. European Journal of Endocrinology. 2011;164:559–567.
Shabestari AN, Mojgan A., Zahra J, Mostafa Q, Roya K. Association of lipid accumulation product with cardio-metabolic risk factors in postmenopausal women. Acta Medica Iranica. 2016; 54:6.
Xin X, Qing L, Lingmin Z, Wei R. Lipid accumulation product, visceral adiposity index, and chinese visceral adiposity index as markers of cardiometabolic risk in adult growth hormone deficiency patients: A cross-sectional study. Endocrine Practice. 2018;24:1.
Nascimento T, Chein MB, Rosângela ML, Alexsandro F, Paula A, Luciane MO. Importance of lipid accumulation product index as a marker of CVD risk in PCOS women. Lipids in Health and Disease. 2015;14:62.
Cheng YL, Yuan-Jen W, Keng-Hsin L, Teh-Ia H, Yi-Hsiang H, Chien-Wei S, Wei-Yao H, Ming-Chih H, Han-Chieh L, Fa-Yauh L, Jaw-Ching W, Shou-Dong L. Fatty liver index and lipid accumulation product can predict metabolic syndrome in subjects without fatty liver disease. Gastroenterology Research and Practice. 2017;9279:836,1-12.
Song J, Xue C, Yuhong J, Jing M, Yuyuan Z, Yingying Z, Xuesen W, Huaiquan G. Association and interaction analysis of lipid accumulation product with impaired fasting glucose risk: A cross-sectional survey. Journal of Diabetes Research; 2019;10, ID 9014698.
Shweta P, Hasmukh S, Singh KS. Relationship between Visceral Fat and Blood Pressure in Indian Adolescents. Natl J Integr Res Med. 2017;8(3):57- 61.
Goldani H, Fernanda SA, Maria TA, Luis HR, Patricia F, Magali TQG, Simone M. Applicability of the visceral adiposity index (VAI) in the prediction of the components of the metabolic syndrome in elderly. Nutr Hosp. 2015;32:1609-1615.
Pineda H, Castro J, Lares M, Huérfano T, Brito S, Velasco M. Lipid accumulation product (LAP) and visceral adiposity index (VAI) a simple and clinically useful surrogate marker for metabolic syndrome and cardiovascular disease predictor in non-diabetic venezuelan adults. J. Pharm Pharm Scien. 2017;2(1):1-8.
Ahn N, Baumeister SE, Amann U. et al. Visceral adiposity index (VAI), lipid accumulation product (LAP), and product of triglycerides and glucose (TyG) to discriminate prediabetes and diabetes. Sci Rep. 2019;9:96-99.
Montani JP, Carroll JF, Dwyer TM, Antic V, Yang Z, Dulloo AG. Ectopic fat storage in heart, blood vessels and kidneys in the pathogenesis of cardiovascular diseases. Int J Obes Relat Metab Disord. 2004; 28(4):58-65.
Unger RH. Weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology. 2003; 144:5159-5165.
Van Pelt RE, Evans EM, Schechtman KB, Ehsani AA, Kohrt WM. Contributions of total and regional fat mass to risk for cardiovascular disease in older women. Am J Physiol Endocrinol Metab. 2002; 282:1023-1028.
Lemieux I. Energy partitioning in gluteal-femoral fat: does the metabolic fate of triglycerides affect coronary heart disease risk?. Arterioscler Thromb Vasc Biol. 2004; 24:795-797.
Savva SC, Lamnisos D, Kafatos AG. Predicting cardiometabolic risk: waist-to-height ratio or BMI. A meta-analysis. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2013;6: 403–419.
Chiang J, Koo M. Lipid accumulation product: a simple and accurate index for predicting metabolic syndrome in Taiwanese people aged 50 and over. BMC Cardiovascular Disorders. 2012;12: 78.
Kumar M, Prashant KG, Mukti N, Rajesh M, Naveen G, Sanjay G, Rupesh T. Association of abdominal fat with blood pressure in normal healthy subjects. Journal, Indian Academy of Clinical Medicine. 2013;14:2.
Abstract View: 262 times
PDF Download: 137 times